News
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
About 7 million people enrolled in Medicare and Medicaid would gain access to weight-loss drugs like Ozempic, Wegovy, Zepbound and Mounjaro, which are not covered by these federal programs, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results